TG Therapeutics TGTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $19.78M-14.2% | $23.04M-94.1% | $390.9M+1,287% | $28.19M+457% | $5.06M-78.3% | ||
| $32K+52.4% | $21K+23.5% | $17K+30.8% | $13K+62.5% | $8K-11.1% | ||
| $19.95M+27.5% | $15.65M-11.5% | $17.69M+8.1% | $16.36M+9.3% | $14.97M+25.3% | ||
| $3.86M— | —— | —— | —— | $0— | ||
| $285K-6.3% | $304K0.0% | $304K0.0% | $304K0.0% | $304K+0.3% | ||
| $86.42M+115% | $40.24M+18.8% | $33.87M-18.2% | $41.4M-32.1% | $60.94M+353% | ||
| $13.28M— | —— | —— | —— | $46.31M+86.6% | ||
| $34.02M+1,594% | $2.01M— | —— | $5.97M-90.8% | $65.18M— | ||
| -$1.62M— | —— | -$277K+46.2% | -$515K+72.2% | -$1.86M-257% | ||
| -$5.99M— | —— | $9.17M+413% | $1.79M+1,176% | $140K— | ||
| -$6.72M— | —— | —— | —— | $408K— | ||
| $1.53M+454% | -$433K-203% | $420K+332% | -$181K-74.0% | -$104K+79.2% | ||
| $573K+32.6% | $432K+0.2% | $431K-0.2% | $432K-4.6% | $453K-9.0% | ||
| -$9.15M— | $0— | —— | —— | $0+100% | ||
| -$424K+18.3% | -$519K0.0% | -$519K-0.2% | -$518K+4.6% | -$543K+9.2% | ||
| -$10.66M-658% | $1.91M-93.8% | $30.63M+482% | $5.26M+13.7% | $4.63M— | ||
| -$17.89M— | —— | -$23.15M— | —— | -$28.72M-12.0% | ||
| $51K-23.9% | $67K-16.3% | $80K+90.5% | $42K+68.0% | $25K+19.0% | ||
| $11.25M-62.5% | $30M-61.4% | $77.75M+57.5% | $49.35M-38.6% | $80.4M+9.1% | ||
| $0— | —— | —— | —— | $1.25M— | ||
| $21.06M-53.8% | $45.57M+45.6% | $31.31M-41.3% | $53.3M-42.1% | $92.06M+59.0% | ||
| -$9.86M— | —— | $46.36M+1,261% | -$3.99M+69.1% | -$12.93M— | ||
| $99.99M— | $0-100% | $78.24M+1,038% | $6.88M+12.3% | $6.12M-7.4% | ||
| $747.66M— | $0— | —— | —— | $0— | ||
| $763K+268% | -$453K— | $0-100% | $432K+1,957% | $21K— | ||
| $2.6M— | $0— | —— | —— | $0-100% | ||
| $390.83M— | $0+100% | -$78.24M-1,114% | -$6.44M-5.6% | -$6.1M— | ||
| $363.07M— | $0+100% | -$55.03M-1,735% | -$3M+93.7% | -$47.75M— | ||
| $2.39M-59.6% | $5.91M-3.1% | $6.1M0.0% | $6.1M-0.7% | $6.14M-4.3% | ||
| $3.44M+307% | $845K-56.8% | $1.96M-61.5% | $5.08M— | $0-100% | ||
| $285K-6.3% | $304K0.0% | $304K0.0% | $304K0.0% | $304K+0.3% | ||
| -$5.99M— | —— | $9.17M+413% | $1.79M+1,176% | $140K— | ||
| -$424K+18.3% | -$519K0.0% | -$519K-0.2% | -$518K+4.6% | -$543K+9.2% | ||
| -$10.66M-658% | $1.91M-93.8% | $30.63M+482% | $5.26M+13.7% | $4.63M— | ||
| -$1.62M— | —— | -$277K+46.2% | -$515K+72.2% | -$1.86M-257% | ||
| —— | $1.54M0.0% | $1.54M0.0% | $1.54M0.0% | $1.54M— | ||
| $367K-4.2% | $383K-51.3% | $786K-38.7% | $1.28M-4.0% | $1.34M-21.3% | ||
| $573K+32.6% | $432K+0.2% | $431K-0.2% | $432K-4.6% | $453K-9.0% | ||
| $0— | —— | —— | —— | $1.25M— | ||
| $21.06M-53.8% | $45.57M+45.6% | $31.31M-41.3% | $53.3M-42.1% | $92.06M+59.0% | ||
| $99.99M— | $0-100% | $78.24M+1,038% | $6.88M+12.3% | $6.12M-7.4% | ||
| $747.66M— | $0— | —— | —— | $0— | ||
| $48K+4.3% | $46K+2.2% | $45K-2.2% | $46K-4.2% | $48K-9.4% | ||
| -$88K— | —— | -$14K— | —— | -$213K-39.2% | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$255M— | $0— | —— | —— | $0+100% | ||
| $1.13M— | —— | —— | —— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $3.44M+307% | $845K-56.8% | $1.96M-61.5% | $5.08M— | $0-100% | ||
| -$17.95M— | —— | -$23.23M— | —— | -$28.74M-12.0% | ||
| -$17.95M— | —— | -$23.23M— | —— | -$28.74M-12.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does TG Therapeutics generate?
- TG Therapeutics (TGTX) generated -$95.4M in operating cash flow over the trailing twelve months.
- What is TG Therapeutics's free cash flow?
- After $240.0K of capital expenditures, TG Therapeutics's free cash flow was -$95.6M over the trailing twelve months, down 66.2% year over year.
- Where does TG Therapeutics's cash flow data come from?
- Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
